HomeCompareXLNX vs PFE

XLNX vs PFE: Dividend Comparison 2026

XLNX yields 8.04% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $21.0K in total portfolio value· pulled ahead in Year 9
10 years
XLNX
XLNX
● Live price
8.04%
Share price
$194.92
Annual div
$15.68
5Y div CAGR
-8.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.6K
Annual income
$493.88
Full XLNX calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — XLNX vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXLNXPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XLNX + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XLNX pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XLNX
Annual income on $10K today (after 15% tax)
$683.77/yr
After 10yr DRIP, annual income (after tax)
$419.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,900.11/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XLNX + PFE for your $10,000?

XLNX: 50%PFE: 50%
100% PFE50/50100% XLNX
Portfolio after 10yr
$39.1K
Annual income
$13,376.30/yr
Blended yield
34.23%
📊

Analyst Conviction Gap

Where Wall Street is split right now

XLNX
Analyst Ratings
16
Buy
28
Hold
1
Sell
Consensus: Hold
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XLNX buys
0
PFE buys
0
No recent congressional trades found for XLNX or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXLNXPFE
Forward yield8.04%6.13%
Annual dividend / share$15.68$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-8.1%13.2%
Portfolio after 10y$28.6K$49.6K
Annual income after 10y$493.88$26,258.71
Total dividends collected$6.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: XLNX vs PFE ($10,000, DRIP)

YearXLNX PortfolioXLNX Income/yrPFE PortfolioPFE Income/yrGap
1$11,439$739.27$9,153$693.39+$2.3KXLNX
2$12,966$726.33$8,593$849.25+$4.4KXLNX
3$14,581$707.11$8,336$1,066.78+$6.2KXLNX
4$16,285$682.95$8,437$1,384.80+$7.8KXLNX
5$18,080$655.11$9,013$1,875.40+$9.1KXLNX
6$19,970$624.68$10,306$2,680.72+$9.7KXLNX
7$21,961$592.62$12,820$4,101.38+$9.1KXLNX
8$24,058$559.72$17,673$6,826.70+$6.4KXLNX
9← crossover$26,268$526.64$27,543$12,591.86$1.3KPFE
10$28,601$493.88$49,560$26,258.71$21.0KPFE

XLNX vs PFE: Complete Analysis 2026

XLNXStock

Xilinx, Inc. designs, develops, and markets programmable devices and associated technologies worldwide. The company offers integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; adaptive compute acceleration platform; software design tools to program the PLDs; software development environments and embedded platforms; targeted reference designs; printed circuit boards; and intellectual property (IP) core licenses covering Ethernet, memory controllers, Interlaken, and peripheral component interconnect express interfaces, as well as domain-specific IP in the areas of embedded, digital signal processing and connectivity, and market-specific IP cores. It also offers development boards; development kits, including hardware, design tools, IP, and reference designs that are designed to streamline and accelerate the development of domain-specific and market-specific applications; and configuration products comprising one-time programmable and in-system programmable storage devices to configure field programmable gate arrays. In addition, it provides design, customer training, field engineering, and technical support services. The company offers its products to electronic equipment manufacturers in sub- markets, such as data center, wireless, wired, aerospace and defense, test, measurement and emulation, industrial, scientific and medical, automotive, audio, video and broadcast, and consumer. It sells its products through a network of independent distributors; and through direct sales to original equipment manufacturers and electronic manufacturing service providers, as well as independent sales representatives. Xilinx, Inc. was incorporated in 1984 and is headquartered in San Jose, California. As of February 14, 2022, Xilinx, Inc. operates as a subsidiary of Advanced Micro Devices, Inc.

Full XLNX Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this XLNX vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XLNX vs SCHDXLNX vs JEPIXLNX vs OXLNX vs KOXLNX vs MAINXLNX vs JNJXLNX vs MRKXLNX vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.